FDA label 6461fd18-6b4d-809a-73f4-fd0c23a99291
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 4c2a1403-3862-1efd-0a91-444989222b37
- SPL ID
- 6461fd18-6b4d-809a-73f4-fd0c23a99291
- Version
- 6
- Effective date
- 2015-09-25
- Source export date
- 2026-10-12
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/a497e765d824a2e2aa9e88d5f0eea2aae9dcba363989e5f163395cda5c3c9dd8/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 02:48:48
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 6461fd18-6b4d-809a-73f4-fd0c23a99291 | id | |
| spl set id | 4c2a1403-3862-1efd-0a91-444989222b37 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Increased risk of bleeding. (5.1) DURLAZA can cause gastric mucosal irritation and bleeding. Patients with a history of active peptic ulcer disease are at particular risk. (5.2) DURLAZA can cause fetal harm when administered to a pregnant woman. (5.3, 8.1) 5.1 Risk of Bleeding DURLAZA increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7) ]. 5.2 Peptic Ulcer Disease DURLAZA may cause gastric ulceration and bleeding. Avoid DURLAZA in patients with active peptic ulcer disease. 5.3 Fetal Toxicity DURLAZA can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because NSAIDs may cause premature closure of the fetal ductus arteriosus, avoid DURLAZA in the third trimester of pregnancy [see Use in Specific Populations (8.1) ].
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Most common adverse reactions are Gastrointestinal (6) To report SUSPECTED ADVERSE REACTIONS, contact New Haven Pharmaceuticals at (877) 824-2483 or www.newhavenpharma.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience The following is a list of adverse reactions that have been reported in the literature for products containing low dose aspirin [see Warnings and Precautions (5) ] . Central Nervous System: Agitation, cerebral edema, coma, confusion, dizziness, headache, lethargy, seizures. Fluid and Electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis. Gastrointestinal: Dyspepsia, hepatic enzyme elevation, hepatitis, Reye's Syndrome. Renal: Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.